arrow
I

Ilary Ruscito

catholic university of the sacred heart
H指数:25
被引数:1,670

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Immunotherapy With or Without PARP Inhibitors in Advanced Ovarian Cancer: A Meta-Analysis including Bevacizumab Use, Molecular Status, and PD-L1 Expression

晚期卵巢癌中一线免疫疗法联合或不联合PARP抑制剂:一项包括贝伐珠单抗使用、分子状态和PD-L1表达的系统评价

2026-05-180
PRE
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy

关于尼拉帕利在原发性输卵管卵巢癌老年患者中的真实世界观察性研究:重点关注安全性与有效性

2025-11-040
OAAI
Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis

铂类再挑战疗法在首次治疗后6个月内复发的上皮性卵巢癌中的应用:一项倾向性评分匹配分析

2025-06-300
PRE
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-11-051
PRE
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-09-095
OAAI
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Parp抑制剂在原发性和复发性卵巢癌中的应用: 12项II/III期随机对照试验的荟萃分析

2020-07-0138
PREAI
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
2020-05-1538
OAAI
Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

基于贝伐单抗的化疗通过促进效应T细胞亚群的募集,触发了多治疗复发性卵巢癌患者的免疫效应

2019-03-1827
OAAI
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study)
2018-06-2917
OAAI
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2017-07-0129
OAAI